Revlimid (lenalidomide) — Medica

Initial criteria

• age ≥ 18 years
• Patient has symptomatic anemia OR transfusion-dependent anemia OR anemia not controlled with an erythropoiesis-stimulating agent OR patient has myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasm with SF3B1 mutation and thrombocytosis

Approval duration

1 year